Clinical Characteristics and Outcomes of Fungal Keratitis in the United Kingdom

2011-2020: A 10-Year Study

Darren Shu Jeng TING, FRCOphth
Mohamed GALAL, FRCS(Ed)
Bina KULKARNI, FRCS(Ed)
Mohamed S. ELALFY, FRCOphth
Damian LAKE, FRCOphth
Samer HAMADA, FRCOphth
Dalia G. SAID, FRCS(Ed), MD
Harminder S. DUA, FRCOphth, PhD

1Academic Ophthalmology, School of Medicine, University of Nottingham, Nottingham, UK; Queen’s Medical Centre, Nottingham, UK. Email: ting.darren@gmail.com

2Queen Victoria Hospital, East Grinstead, UK. Email: mohamed.galal@nhs.net

3Department of Ophthalmology, Queen’s Medical Centre, Nottingham, UK. Email: Bina.Kulkarni@nuh.nhs.uk

4Queen Victoria Hospital, East Grinstead, UK; Research Institute of Ophthalmology, Giza, Egypt. Email: m.elalfy@nhs.net

5Queen Victoria Hospital, East Grinstead, UK. Email: damian.lake@nhs.net

6Queen Victoria Hospital, East Grinstead, UK. Email: s.hamada@nhs.net

7Academic Ophthalmology, School of Medicine, University of Nottingham, Nottingham, UK; Department of Ophthalmology, Queen’s Medical Centre, Nottingham, UK; Research Institute of Ophthalmology, Giza, Egypt. Email: daliagsaid@gmail.com

8Academic Ophthalmology, School of Medicine, University of Nottingham, Nottingham, UK; Queen’s Medical Centre, Nottingham, UK. Email: profdua@gmail.com
Corresponding author: Darren Shu Jeng Ting

Corresponding address: Academic Ophthalmology, Division of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham, NG7 2RD, UK

Email: ting.darren@gmail.com

Funding / Support: D.S.J.T. acknowledges support from the Medical Research Council / Fight for Sight Clinical Research Fellowship (MR/T001674/1) and the Fight for Sight / John Lee, Royal College of Ophthalmologists Primer Fellowship (24CO4).

Conflict of interest: None
ABSTRACT

Fungal keratitis (FK) is a serious ocular infection that often poses significant diagnostic and therapeutic dilemmas. This study aimed to examine the causes, clinical characteristics, outcomes, and prognostic factors of FK in the UK. All culture-positive and culture-negative presumed FK (with complete data) that presented to Queen's Medical Centre, Nottingham, and Queen Victoria Hospital, East Grinstead, between 2011 and 2020 were included. A total of 117 patients (n=117 eyes) with FK were included in this study. The mean age was 59.0 ± 19.6 years (range, 4-92 years) and 51.3% patients were female. Fifty-three fungal isolates were identified from 52 (44.4%) culture-positive cases, with Candida spp. (33, 62.3%), Fusarium spp. (9, 17.0%), and Aspergillus spp. (5, 9.4%) being the most common organisms. Ocular surface disease (60, 51.3%), prior corneal surgery (44, 37.6%), and systemic immunosuppression (42, 35.9%) were the three most common risk factors. Hospitalisation for intensive treatment was required for 95 (81.2%) patients, with a duration of 18.9±16.3 days. Sixty-six (56.4%) patients required additional surgical interventions for eradicating the infection. Emergency therapeutic/tectonic keratoplasty was performed in 29 (24.8%) cases, though 13 (44.8%) of them failed at final follow-up. The final corrected-distance-visual-acuity (CDVA) was 1.67±1.08 logMAR. Multivariable logistic regression analyses demonstrated increased age, large infiltrate size (>3mm), and poor presenting CDVA (<1.0 logMAR) as significant negative predictive factors for poor visual outcome (CDVA of <1.0 logMAR) and poor corneal healing (>60 days of healing time or occurrence of corneal perforation requiring emergency keratoplasty; all p<0.05). In conclusion, FK represents a difficult-to-treat ocular infection that often results in poor visual outcome, with a high need for surgical interventions. Innovative treatment strategies are urgently required to tackle this unmet need.

Keywords: Candida; Corneal infection; Corneal ulcer; Contact lens; Fungal infection; Fusarium; Infectious keratitis; Keratoplasty
INTRODUCTION

Infectious keratitis (IK) represents the leading cause of corneal blindness globally, with an estimated incidence of 2.5-799 cases per 100,000 population/year.\textsuperscript{1-3} Subject to geographical, temporal and seasonal variations, bacteria and fungi are the most common causative organisms for IK, while viral and parasitic infections are less commonly reported.\textsuperscript{3-9} The variations in the incidence and causes are mainly attributed to underlying discrepancy in the risk factors (particularly contact lens wear, trauma and ocular surface disease), climate, access to healthcare system, personal and environmental hygiene, and level of education.\textsuperscript{1}

Fungal keratitis (FK) often poses significant diagnostic and therapeutic dilemmas. It is most commonly observed in tropical / subtropical countries and regions with prevalent agricultural activity, accounting for 23-63% of all IK cases in these regions.\textsuperscript{1,10,11} Compared to bacterial keratitis, FK is more frequently associated with guarded visual prognosis, primarily caused by significant diagnostic challenge (due to low and slow culture yield), propensity to deeper infection affecting the posterior cornea, limited antifungal treatment option, and resistance to treatment.\textsuperscript{4,12} In addition, many cases of FK usually require therapeutic keratoplasty to achieve completion resolution of the disease, with many of them affected by recurrence of infection or uncontrolled infection progressing to endophthalmitis and eventuating in evisceration / enucleation.\textsuperscript{12-16}

To date, the majority of the FK studies reported in the literature were conducted in developing or tropical / subtropical regions, including India, China and Nepal, where FK is more prevalent.\textsuperscript{4,17-23} However, the results of those studies may not be readily applicable to populations in developed or temperate regions as the population characteristics, risk factors, underlying causes and management of FK can vary significantly.\textsuperscript{1} So far, there was only one large study that had specifically examined the outcome of FK in the United Kingdom (UK) in the past decade.\textsuperscript{24} In view of the paucity of the literature and the clinical significance of the...
disease, this study aimed to examine the clinical characteristics, risk factors, outcomes, and prognostic factors of FK in the UK.

MATERIALS AND METHODS
This was a retrospective study of all cases of FK that presented to two of the tertiary ophthalmic referral centres in the UK, namely the Queen’s Medical Centre, Nottingham, and the Queen Victoria Hospital, East Grinstead, between January 2011 and December 2020 (a 10-year period). Ethical approval was waived as the study was considered as a clinical audit and it was approved by the local clinical governance team of Nottingham University Hospitals NHS Trust, Nottingham, UK, in June 2019 (Reference: 19-265C) and by the clinical governance team of Queen Victoria Hospital NHS Foundation Trust, East Grinstead, UK, in January 2021 (Reference: 21-539). Informed patient consent was not required as this retrospective study was a clinical audit of the medical case notes, with no patient identifiable information being used. Additionally, all the treatment provided in this study formed part of the standard care in our routine clinical practice.

Case identification and definition
Potential cases of FK were first identified via the local microbiological database and hospital pharmacy database (based on the use of topical antifungal treatment). Subsequently, the medical case records were examined to confirm the eligibility of the potential cases prior to inclusion into the study. In anticipation of the low prevalence of FK in the UK, both culture-positive and culture-negative presumed FK cases were included in this study. Culture-positive FK was defined as the presence of clinical FK with confirmation of the causative fungal pathogen on microbiological culture. Culture-negative presumed FK was diagnosed based on the presence of typical clinical findings (see below) and/or suggestive clinical course such as non-improvement / deterioration with intensive topical antibiotic treatment alone, which subsequently required intensive topical antifungal treatment to improve and resolve the infection. Co-infection of FK with culture-positive bacterial keratitis cases were
included but pure bacterial keratitis cases were excluded from this study. Other types of infection, including viral and parasitic keratitis, were also excluded from this study.

Data collection

Relevant data, including demographic factors, risk factors, clinical characteristics, types of fungi, corrected-distance-visual-acuity (CDVA), pre-existing ocular co-morbidities that could affect the visual prognosis, management, outcome and complications, were collected using a standardised Microsoft Excel proforma. Risk factors were divided into: (1) contact lens wear; (2) trauma; (3) ocular surface diseases (e.g. dry eye, meibomian gland dysfunction, neurotrophic keratopathy, previous corneal infection, recurrent corneal erosion syndrome, limbal stem cell deficiency, cicatricial conjunctivitis, band keratopathy, and bullous keratopathy); (4) lid diseases (e.g. entropion, ectropion, distichiasis/trichiasis, and exposure keratopathy); (5) use of topical corticosteroids; (6) previous/recent history of corneal surgery (e.g. corneal graft, pterygium surgery, corneal collagen cross-linking and corneal debridement/delamination); and (7) systemic immunosuppression (e.g. diabetes, systemic immunosuppressive treatment, malnutrition, and immunodeficiency). Slit-lamp photographs and anterior segment optical coherence tomography (AS-OCT) were examined for the presence of any typical characteristics of FK, including feathery border of the infiltrate, ring infiltrate, satellite lesions (small infiltrates near the main infiltrative lesion), multifocal lesions (≥2 infiltrates either close or far apart from each other), and deep stromal/endothelial plaque (Figure 1A-C).

A number of clinical parameters used in this study were defined based on our previous study. The size of epithelial defect and infiltrate was categorised as very small (<1 mm), small (1-3 mm), moderate (3.1-6 mm), or large (>6 mm), based on the maximum linear dimension. The location of the ulcer was divided into central (any part of the ulcer affecting the visual axis), paracentral (in between the central and peripheral location), and peripheral (the entire ulcer was within 3 mm from the limbus). Recurrence was defined as the re-
occurrence of FK after complete resolution of the previous FK episode, irrespective of the time interval between the first and subsequent infective episode. To avoid any duplication of the patient’s risk factors in bilateral or recurrent FK cases, we only included one eye per patient in this study. For recurrent cases, only the first FK episode was included and analysed, regardless of the laterality of infection in the subsequent infective episode.

![Figure 1](image)

**Figure 1.** Slit-lamp photography demonstrating typical signs of fungal keratitis (FK). (A) A small contact lens (CL)-related FK with multifocal infiltrates (*green arrows*) with feathery borders. (B) A CL-related FK with multifocal infiltrates of feathery borders, with an area of main infiltrate (*blue arrow*) and three satellites lesions (*red arrows*). (C) A case of severe FK with hypopyon, ring infiltrate (*blue arrows*) and endothelial plaque (*yellow arrow*).

**Microbiological culture, diagnosis and treatment**

Based on the departmental guideline for IK, all patients presented with corneal ulcer(s) of >1 mm diameter, central location or sight-threatening, associated with significant anterior chamber reaction, or atypical presentation were subjected to microbiological investigation such as corneal scraping for microscopy (with Gram staining), microbiological culture and sensitivity testing. Corneal scrapes were inoculated on chocolate agar (for fastidious organisms), blood agar (for bacteria), and Sabouraud dextrose agar (for fungi). For suspected cases of Acanthamoeba keratitis, corneal swab and/or epithelial biopsy was obtained for polymerase chain reaction (PCR) testing. All cultures were incubated for at least 1 week (and up to 3 weeks for suspected Acanthamoeba keratitis). In vivo confocal...
microscopy (IVCM) using the Heidelberg Retinal Tomography (HRT) II/III with Rostock Cornea Module (Heidelberg Engineering Ltd, Hertfordshire, UK) was utilised to aid the diagnosis or exclusion of fungal and Acanthamoeba keratitis.

During the initial treatment phase, all patients with FK were treated with intensive hourly antifungal topical treatment, using either voriconazole 1%, natamycin 5%, amphotericin B 0.15% or a combination of them, based on the severity of infection, types of fungi, and clinicians’ preference. Further modification to the treatment regimen and addition of oral antifungal treatment were made according to the patient’s clinical progress and culture results.

**Statistical analysis**

Statistical analysis was performed using SPSS version 27.0 (IBM SPSS Statistics for Windows, Armonk, NY, USA). For descriptive and analytic purposes, the cases were divided into culture-positive and culture-negative FK cases. Comparison between groups was conducted using Pearson’s Chi square or Fisher’s Exact test where appropriate for categorical variables, and T test or Mann-Whitney U test for continuous variables. Normality of data distribution was assumed if the skewness and kurtosis z-values were between -1.96 and +1.96 and the Shapiro-Wilk test p-value was >0.05. All continuous data were presented as mean ± standard deviation (SD) and/or 95% confidence interval (CI).

The main outcome measures were corrected-distance-visual-acuity (CDVA) and time to complete corneal healing, defined as complete resolution of infection with corneal re-epithelialisation. Snellen vision was converted to logMAR vision for analytic purpose. Counting fingers (CF), hand movement (HM), perception to light (PL) and no perception to light (NPL) were quantified as 1.9 logMAR, 2.3 logMAR, 2.8 logMAR and 3.0 logMAR respectively.\(^{25,26}\) For patients who underwent keratoplasty (either therapeutic, tectonic or optical), the CDVA immediately prior to keratoplasty was used as the final visual outcome. A
final CDVA of 3.0 logMAR was assigned to cases that eventuated with evisceration or enucleation. Logistic regression analysis was performed to examine for any potential prognostic factors for poor visual outcome, defined as corrected-distance-visual-acuity (CDVA) of <1.0 logMAR (or <6/60), and poor corneal healing, defined as >60 days to achieve complete corneal healing from the initial presentation or required tectonic / therapeutic keratoplasty, evisceration or enucleation to resolve the infection. P-value of <0.05 was considered statistically significant.

RESULTS

Overall description

During the 10-year study period, 117 patients (n=117 eyes) with FK were included. The mean age was 59.0 ± 19.6 years (range, 4-92 years), 51.3% patients were female, and 57.3% cases affected the right eye (Table 1). The mean follow-up duration was 26.2 ± 26.5 months. A total of 52 (44.4%) culture-positive FK cases and 65 (55.6%) culture-negative presumed FK cases were included (Table 1). Thirty-two (27.3%) cases were treated as mixed bacterial/fungal keratitis.

Causative organisms and risk factors

Candida spp. (33, 62.3%) was shown to be the most common fungal pathogen, followed by Fusarium spp. (9, 17.0%), and Aspergillus spp. (5, 9.4%; Table 2). Almost all (51, 98.1%) cases were caused by a single fungal pathogen, except for one (1.9%) case which was caused by poly-fungal infection secondary to Rhodotorula spp. and Alternaria spp. Of all cases, 32 (27.3%) cases were affected by bacterial co-infection, with Staphylococci spp. (16, 13.7%) as the most common cause. No significant difference in age (p=0.14), gender (p=0.34), and hospital location (p=0.57) was found between yeast and filamentous FK (Table 3).
| Parameters | All cases | Culture-proven | Culture-negative | P-value<sup>+</sup> |
|-----------|----------|----------------|------------------|-----------------|
| Hospital  |          |                |                  |                 |
| QVH       | 87 (74.4)| 35 (67.3)      | 52 (80.0)        | 0.12            |
| QMC       | 30 (25.6)| 17 (32.7)      | 13 (20.0)        |                 |
| Age, years|          |                |                  | 0.21            |
|           | 59.0 ± 19.6| 56.5 ± 20.8  | 61.1 ± 18.5      |                 |
| Gender    |          |                |                  | 0.11            |
| Female    | 60 (51.3)| 31 (59.6)      | 29 (44.6)        |                 |
| Male      | 57 (48.7)| 21 (40.4)      | 36 (55.4)        |                 |
| Laterality|          |                |                  | 0.23            |
| Left      | 50 (42.7)| 19 (36.5)      | 31 (47.7)        |                 |
| Right     | 67 (57.3)| 33 (63.5)      | 34 (52.3)        |                 |
| Risk factors<sup>§</sup> |        |                |                  | 0.37            |
| OSD*      | 60 (51.3)| 30 (57.7)      | 30 (46.2)        |                 |
| Prior corneal surgery | 44 (37.6)| 18 (34.6)      | 26 (40.0)        |                 |
| Immunosuppression** | 42 (35.9)| 21 (40.4)      | 21 (32.3)        |                 |
| Contact lens wears | 28 (23.9)| 17 (32.7)      | 11 (16.9)        |                 |
| Topical corticosteroids | 19 (16.2)| 10 (19.2)      | 9 (13.8)         |                 |
| Lid diseases*** | 16 (13.7)| 4 (7.7)       | 12 (18.5)        |                 |
| Trauma    | 7 (6.0)  | 3 (5.8)        | 4 (6.2)          |                 |
| Presenting CDVA, in logMAR |       |                |                  | 0.038           |
| 0.0 – 0.3 | 16 (13.7)| 10 (19.3)      | 6 (9.2)          |                 |
| <0.3 – 0.6| 7 (6.0)  | 4 (7.7)        | 3 (4.6)          |                 |
| <0.6–1.0  | 11 (9.4) | 8 (15.4)       | 3 (4.6)          |                 |
| <1.0      | 83 (70.9)| 30 (57.7)      | 53 (81.5)        |                 |
| Size of epithelial defect |     |                |                  | 0.22            |
| Very small (<1mm) | 6 (5.1)| 2 (3.8)        | 4 (6.2)          |                 |
| Small (1-3mm) | 38 (32.5)| 19 (36.5)      | 19 (29.2)        |                 |
| Moderate (3.1-6mm) | 45 (38.5)| 23 (44.2)      | 22 (33.8)        |                 |
| Large (>6mm) | 28 (23.9)| 8 (15.4)       | 20 (30.8)        |                 |
| Size of infiltrate |     |                |                  | 0.52            |
| Very small (<1mm) | 10 (8.5)| 5 (9.6)        | 5 (7.7)          |                 |
| Small (1-3mm) | 45 (38.5)| 21 (40.4)      | 24 (36.9)        |                 |
| Moderate (3.1-6mm) | 47 (40.2)| 22 (42.3)      | 25 (38.5)        |                 |
| Large (>6mm) | 15 (12.8)| 4 (7.7)        | 11 (16.9)        |                 |
| Location  |          |                |                  | 0.71            |
| Central   | 70 (59.8)| 29 (55.8)      | 41 (63.1)        |                 |
| Paracentral | 34 (29.0)| 17 (32.7)      | 17 (26.2)        |                 |
| Peripheral| 13 (11.1)| 6 (11.5)       | 7 (10.8)         |                 |
| Hypopyon  |          |                |                  | 0.76            |
| Yes       | 40 (34.2)| 17 (32.7)      | 23 (35.4)        |                 |
| No        | 77 (65.8)| 35 (67.3)      | 42 (64.6)        |                 |
| Hospitalisation required |     |                |                  | 0.29            |
| Yes       | 95 (81.2)| 40 (76.9)      | 55 (84.6)        |                 |
| No        | 22 (18.8)| 12 (33.1)      | 10 (15.4)        |                 |
| Duration of hospitalisation, days | 18.9 ± 16.3| 17.5 ± 15.0  | 19.8 ± 17.2      | 0.50            |
| Co-infection with bacteria |     |                |                  | 0.18            |
| Yes       | 32 (27.3)| 11 (21.2)      | 21 (32.3)        |                 |
| No        | 85 (72.7)| 41 (78.8)      | 44 (67.7)        |                 |
| Need for surgical intervention(s) |     |                |                  | 0.62            |
| Yes       | 66 (56.4)| 28 (53.8)      | 38 (58.5)        |                 |
| No        | 51 (43.6)| 24 (46.2)      | 27 (41.5)        |                 |
OSD = Ocular surface disease; CDVA = Corrected-distance-visual-acuity
Continuous values are presented as mean ± standard deviation (SD).
*Some patients had more than 1 risk factor identified.
*Included dry eye disease, meibomian gland disease, neurotrophic keratopathy, previous corneal infection, corneal erosion syndrome, limbal stem cell deficiency, cicatricial conjunctivitis, band keratopathy, and bullous keratopathy.
**Included diabetes, use of systemic immunosuppressive drugs, malnutrition, and immunodeficiency.
***Included lid ectropion, entropion, distichiasis/trichiasis, and exposure keratopathy.
#Comparison between culture-positive and culture-negative cases. Chi-square and unpaired T-test were used for categorical and continuous variables, respectively. The significant value is underlined.

All (100%) patients were found to have at least one risk factor, with ocular surface disease (60, 51.3%), prior corneal surgery (44, 37.6%), and systemic immunosuppression (42, 35.9%) as the most common risk factors (Table 1). Ocular surface disease was the most common risk factor for both yeast and filamentous FK (Table 3). Contact lens wear was more commonly associated with filamentous FK than yeast FK (50.0% vs. 18.2%; p=0.017) whereas prior corneal surgery and use of topical corticosteroids were more commonly observed in yeast FK than filamentous FK, though statistical significance was not achieved (both p>0.05).

Clinical characteristics

The baseline clinical characteristics are summarised in Table 1. The mean interval between the onset of symptoms and the first presentation to the ophthalmic team was 9.5 ± 14.9 days. At baseline, 83 (70.9%) patients presented with a CDVA of <1.0 logMAR. The most frequently observed clinical characteristics of the ulcer were moderate epithelial defect size (45, 38.5%), moderate infiltrate size (47, 40.2%), central location (64, 59.8%), and absence of hypopyon (77, 65.8%). Hospitalisation for intensive treatment was required in 95 (81.2%) patients, with a mean hospitalisation duration of 18.9 ± 16.3 days. Except for presenting CDVA (p=0.038), there was no significant difference in the demographic factors, risk factors and baseline clinical characteristics between culture-positive and culture-negative FK cases (all p>0.05; Table 1). Typical clinical features of FK were present in 93 (79.5%) cases, with feathery border (52, 44.4%), satellite lesions (39, 33.3%), and deep stromal / endothelial plaque (39, 33.3%) being the most common features (Table 4). No significant difference in the typical features was noted between culture-positive and culture-negative cases.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 6 October 2021
doi:10.20944/preprints202110.0104.v1

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 6 October 2021
doi:10.20944/preprints202110.0104.v1
Table 2. Causative organisms of fungal keratitis and/or co-infection with bacteria that presented to the Queen’s Medical Centre, Nottingham, UK, and Queen Victoria Hospital, East Grinstead, UK, between 2011 and 2020.

| Organisms                                      | N (%)   |
|------------------------------------------------|---------|
| **Fungi**                                      |         |
| Total                                          | 53 (100)|
| Yeast                                          | 33 (62.3)|
| *Candida* spp.                                 | 33 (62.3)|
| Filamentous fungi                              | 19 (35.8)|
| *Fusarium* spp.                                | 9 (17.0)|
| *Aspergillus* spp.                             | 5 (9.4)|
| *Pениophora* spp.                              | 2 (3.8)|
| *Acremonium* spp.                              | 1 (1.9)|
| *Scedosporium* spp.                            | 1 (1.9)|
| Mixed yeast and filamentous infection          | 1 (1.9)|
| *Rhodotorula* spp. + *Alternaria* spp.         | 1 (1.9)|
| **Bacteria (co-infection with fungal keratitis)** |         |
| Total**                                        | 32 (27.4)|
| Gram-positive                                  | 22 (18.8)|
| *Staphylococci* spp.                           | 16 (13.7)|
| *Streptococcus pneumonia*                      | 3 (2.6)|
| *Bacillus* spp.                                | 2 (1.7)|
| *Enterococcus faecalis*                        | 1 (0.9)|
| Gram-negative                                  | 10 (8.)|
| *Moraxella* spp.                               | 3 (2.6)|
| *Serratia marcescens*                          | 3 (2.6)|
| *Pseudomonas* spp.                             | 2 (1.7)|
| *Haemophilus influenza*                        | 1 (0.9)|
| *Acinetobacter lwoffii*                        | 1 (0.9)|

*A case of poly-fungal keratitis.

**Percentage calculated based on all the included cases of fungal keratitis (n=117).
Table 3. Summary of demographic factors and risk factors based on types of fungal keratitis (FK).

| Parameters      | Yeast FK Total N = 33; N (%) | Filamentous FK Total N = 18; N (%) | P-value* |
|-----------------|------------------------------|-----------------------------------|----------|
| Age             | 60.2 ± 18.9                  | 51.3 ± 22.9                       | 0.14     |
| Gender          |                              |                                   | 0.34     |
| Female          | 21 (63.6)                    | 9 (50.0)                          |          |
| Male            | 12 (36.4)                    | 9 (50.0)                          |          |
| Hospital        |                              |                                   | 0.57     |
| QVH             | 21 (63.6)                    | 10 (55.6)                         |          |
| QMC             | 12 (36.4)                    | 8 (44.4)                          |          |
| Risk factors‡   |                              |                                   | 0.31     |
| OSD             | 14 (42.4)                    | 11 (61.1)                         | 0.20     |
| Prior corneal surgery | 7 (21.2) | 2 (11.1)                         | 0.37     |
| Immunosuppression** | 8 (24.2) | 7 (38.9)                         | 0.27     |
| Contact lens wear | 6 (18.2) | 9 (50.0)                         | 0.017    |
| Topical corticosteroids | 6 (18.2) | 1 (5.6)                          | 0.21     |
| Trauma          | 2 (6.1)                      | 1 (5.6)                           | 0.94     |

A case of poly-fungal keratitis, caused by both yeast and filamentous fungi, was excluded from the analysis.

OSD = Ocular surface disease (including lid diseases due to small number)

*Comparison between yeast-like and filamentous FK cases. Chi-square and unpaired T-test were used for categorical and continuous variables, respectively. The significant value is underlined.

‡Some patients had more than 1 risk factor identified.
Table 4. Typical clinical signs of culture-positive and culture-negative fungal keratitis.

| Clinical features                  | All cases | Culture-positive | Culture-negative | P-value |
|-----------------------------------|-----------|------------------|------------------|---------|
|                                   | Total N = 117; | Total N = 52;    | Total N = 65;    |         |
|                                   | N (%)     | N (%)            | N (%)            |         |
| Feathery border                   | 52 (44.4) | 25 (48.1)        | 27 (41.5)        | 0.80    |
| Satellite lesions                 | 39 (33.3) | 16 (30.8)        | 23 (35.4)        |         |
| Deep stromal / endothelial plaque | 39 (33.3) | 14 (26.9)        | 25 (38.5)        |         |
| Multifocal lesion                 | 32 (27.4) | 15 (28.8)        | 17 (26.2)        |         |
| Ring infiltrate                   | 29 (24.8) | 13 (25.0)        | 16 (24.6)        |         |

Number of typical clinical signs 0.74

| Number of typical clinical signs | All cases | Culture-positive | Culture-negative |
|---------------------------------|-----------|------------------|------------------|
| None                            | 24 (20.5) | 12 (23.1)        | 12 (18.5)        |
| 1                               | 31 (26.5) | 15 (28.8)        | 16 (24.6)        |
| 2                               | 35 (29.9) | 13 (25.0)        | 22 (33.8)        |
| 3 or more                       | 27 (23.1) | 12 (23.1)        | 15 (23.1)        |

Medical and surgical treatment

A total of 51 (43.6%) patients were successfully treated with medical treatment alone, with 66 (56.4%) patients requiring additional surgical interventions for controlling the infection and/or its sequelae. The most common choice of topical antifungal treatment was natamycin (63, 53.8%), voriconazole / other azole drops (57, 48.7%), and amphotericin (51, 43.6%). Adjuvant oral antifungal treatment and intrastromal voriconazole injections were administered in 19 (16.2%) patients and 2 (1.7%) patients, respectively. Emergency therapeutic / tectonic keratoplasty (29, 24.8%) was the most commonly performed surgery, followed by amniotic membrane transplant (18, 15.4%), corneal gluing (17, 14.5%), temporary / permanent tarsorrhaphy (17, 14.5%), evisceration (9, 7.7%), enucleation (2, 1.7%), therapeutic corneal cross-linking (1, 0.9%), and conjunctival hooding (1, 0.9%). Of the 29 tectonic / therapeutic keratopathy, 13 (44.8%) of them failed at the final follow-up (mean duration = 24.3 ± 22.7 months). In addition, 10 (8.5%) patients required elective optical penetrating keratoplasty after the resolution of infection.
Clinical outcomes and prognostic factors

The mean CDVA (in logMAR) was similar between initial presentation and final follow-up (1.73 ± 0.90 vs. 1.67 ± 1.08; p=0.36). From initial presentation to final follow-up, the proportion of patients with CDVA of ≥1.0 logMAR improved from 29.1% to 36.8%, though not statistically significant (p=0.21; Figure 2). Twenty-nine (24.8%) patients had a final CDVA of PL or worse, including 11 (9.4%) patients that eventually required evisceration or enucleation. Multivariable logistic regression demonstrated that poor visual outcome (CDVA <1.0 logMAR) was significantly influenced by age >50 years old (OR 4.72; 95% CI, 1.40-15.89; p=0.012), presenting CDVA of <1.0 logMAR (OR 14.92; 95% CI, 4.19-53.18; p<0.001), and infiltrate size >3mm (OR 3.61; 95% CI, 1.11-11.81; p=0.034; Table 5).

A total of 97 (82.9%) patients achieved complete corneal healing at final follow-up, with 11 (9.4%) patients requiring evisceration / enucleation. Seven (6.0%) patients were still undergoing active antifungal treatment at final follow-up. The mean healing time was 2.71 ± 2.86 months, with 83 (70.9%) patients having a corneal healing time of >60 days.

Multivariable logistic regression analysis demonstrated that poor corneal healing was significantly affected by age >50 years (OR 5.81; 95% CI, 1.83-18.37; p=0.003), presenting CDVA of <1.0 logMAR (OR 3.91; 95% CI, 1.19-12.82; p=0.025), and infiltrate size >3mm (OR 3.91; 95% CI, 1.18-12.88; p=0.025; Table 5). Other factors such as gender, ulcer location, presence of hypopyon, culture results, and co-infection with bacteria did not significantly influence the visual outcome or the corneal healing time (all p>0.05).

Complications

There were various complications noted in this study, including threatened / actual corneal perforation (38, 32.5%), complete loss of vision / NLP (18, 15.4%), new onset of raised intraocular pressure (>21 mmHg) / glaucoma (14, 12.0%), recurrence of infection (12, 10.3%), endophthalmitis (6, 5.1%), and loss of eye (11, 9.4%).
Table 5. Prognostic factors for poor visual outcome [defined as corrected-distance-visual-acuity (CDVA) of <1.0 logMAR] and poor corneal healing (defined as >60 days to achieve complete healing or required tectonic / therapeutic keratoplasty, evisceration or enucleation) in fungal keratitis in the UK.

| Parameters                          | Poor visual outcome | Poor corneal healing |
|-------------------------------------|---------------------|----------------------|
|                                     | Odd ratio (95% CI)  | P-value*             | Odd ratio (95% CI)  | P-value*             |
| Age > 50 years                      | 4.72 (1.40 – 15.89) | 0.012                | 5.81 (1.83 – 18.37) | 0.003                |
| Male gender                         | 0.99 (0.33 – 3.00)  | 0.99                 | 0.93 (0.33 – 2.72)  | 0.91                 |
| Right eye                           | 1.13 (0.37 – 3.43)  | 0.83                 | 2.86 (0.95 – 8.61)  | 0.06                 |
| Presenting CDVA <1.0                | 14.92 (4.19 – 53.18)| <0.001               | 3.91 (1.19 – 12.82) | 0.025                |
| Infiltrate size >3mm                | 3.61 (1.11 – 11.81) | 0.034                | 3.91 (1.18 – 12.88) | 0.025                |
| Central ulcer                       | 1.51 (0.50 – 4.53)  | 0.47                 | 1.58 (0.55 – 4.58)  | 0.40                 |
| Presence of hypopyon                | 2.87 (0.81 – 10.18) | 0.10                 | 2.78 (0.78 – 9.86)  | 0.12                 |
| Culture results                     | 0.88                |                      |                      | 0.44                 |
| Negative                            | Reference           | -                    | Reference           | -                    |
| Yeast                               | 1.36 (0.37 – 4.97)  | 0.64                 | 1.67 (0.49 – 5.76)  | 0.42                 |
| Filamentous                         | 0.95 (0.19 – 4.71)  | 0.95                 | 2.74 (0.52 – 14.41) | 0.23                 |
| Co-infection with bacteria          | 1.70 (0.49 – 5.93)  | 0.40                 | 0.71 (0.23 – 2.26)  | 0.57                 |

*Multivariable logistic regression analysis was performed. Significant p-values are underlined.

Figure 2. Comparison of corrected-distance-visual-acuity (CDVA) at initial presentation and at final follow-up.
DISCUSSION

FK is a challenging clinical entity that often results in significant visual impairment and/or blindness. The annual incidence of FK has been estimated to be >1 million worldwide, highlighting the global impact of this disease.\textsuperscript{10} Within the UK, several large epidemiological studies have reported a prevalence of 3.0-7.1\% of FK among all IK cases.\textsuperscript{3,27-29} However, there is a lack of literature related to clinical studies on FK in the UK despite its clinical significance and impact. To the best of our knowledge, our study represents the first multi-centre study in the UK that had specifically examined the risk factors, causes, and clinical outcome of FK.

Studies have shown that the causative organisms of FK are influenced by the climates.\textsuperscript{1,4,10,17,21,30} Yeast or yeast-like fungi such as Candida spp. are more commonly observed in temperate regions whereas filamentous fungi, particularly Fusarium spp. and Aspergillus spp., normally thrive in tropical climates.\textsuperscript{1,17} In this study, we observed that Candida spp. accounted for the majority (62.3\%) of the culture-positive FK, followed by Fusarium spp. (17.0\%). This was similar to a previous London study where Candida spp. was responsible for 60\% of all FK cases,\textsuperscript{31} though a recent London study\textsuperscript{24} observed Fusarium spp. (40.5\%) as the most common organism of FK, closely followed by Candida spp. (38.0\%). Khoo et al.\textsuperscript{32} similarly reported Candida spp. as the most common (29.2\%) fungal isolate for FK in Sydney, which falls in the temperate region. In contrast, the Asian Cornea Society Infectious Keratitis Study (ACSIKS), a large multi-centre study consisting of 8 countries and >6000 patients with infectious keratitis, demonstrated that filamentous fungi such as Fusarium spp. (18.3\%) and Aspergillus spp. (8.3\%) were two of the top three organisms of all IK in this region, particularly India and China.\textsuperscript{4} Similarly, the Queensland Microbial Keratitis Database demonstrated filamentous fungi as the most common group of fungal pathogens (76.9\%) in Queensland, which is mainly a tropical and subtropical region.\textsuperscript{2}
Risk factors of FK have also been shown to vary considerably among different geographical regions. More importantly, the underlying risk factors have an important contributory role to the causative fungal pathogen. Corneal trauma with vegetative matter was consistently reported as the most common risk factor of FK in developing countries, particularly those with high agricultural activity. These FK cases were frequently caused by filamentous fungi, namely *Fusarium spp.* and *Aspergillus spp.* This could help explain the low prevalence of filamentous FK in our study where trauma only accounted for 6.0% of all FK cases. In addition, contact lens wear has been shown to be more commonly implicated in filamentous FK than yeast FK, which was demonstrated by our study and other studies.

On the other hand, yeast infection, particularly *Candida spp.*, were commonly observed in eyes with ocular surface diseases, previous history of corneal transplantation and use of topical corticosteroids. We similarly observed that yeast was more commonly associated with prior corneal surgery and use of topical corticosteroids, though not statistically significant, likely due to a type II error as a result of low sample size. With the shifting trend in penetrating keratoplasty to lamellar keratoplasty, interface infectious keratitis, including Candida-related infection following endothelial keratoplasty, has become increasingly common in clinic and poses significant diagnostic and therapeutic challenges. Therefore, knowledge of the risk factors can provide useful clues to the underlying causative organisms, potentially guiding the choice of antifungal treatment, especially in culture-negative FK cases.

Ocular surface disease (51.3%) and prior corneal surgeries (37.6%) were shown to be the main risk factor of FK in this study. These findings could be attributed to the nature and scope of ophthalmic work provided by the two included study centres, namely the Queen’s Medical Centre, Nottingham, and the Queen Victoria Hospital, East Grinstead. Both centres were tertiary ophthalmic referral centres in the UK where complex ocular surface cases such as cicatricial conjunctival diseases, graft-versus-host-disease, limbal stem cell deficiency and neurotrophic keratopathy, amongst others, were being managed, in addition to common
conditions such as dry eye disease and infectious keratitis. In addition, there was also a relatively low prevalence of trauma and less agricultural activities in the UK, compared to other countries like India and China where trauma is a common risk factor.

In this study, 63% of the patients had a final vision of <1.0 logMAR (mean vision = 1.67 ± 1.08). In addition, 25% of the patients required emergency tectonic / therapeutic keratoplasty, highlighting the significant impact of this disease. The poor outcome was similarly observed by Khoo et al., who reported a median final vision of 1.5 logMAR in patients with FK. In addition, various studies have reported that 25-50% of the patients with FK required additional surgical interventions to resolve the infection, most commonly in the form of therapeutic / tectonic keratoplasty. Therapeutic corneal cross-linking (CXL) has also recently emerged as an attractive adjuvant therapy for treating infectious keratitis, although the benefit for FK remained elusive. In this study, therapeutic CXL was performed in one patient, which successfully controlled the infection and prevented corneal perforation and the need for emergency keratoplasty. However, it is also important to note that infectious keratitis may also occur following CXL, which has been shown in our study (one patient) and other studies.

Prajna et al. previously demonstrated that the visual outcome (at 3 months) was significantly affected by older age, worse presenting visual acuity, and larger presenting infiltrate size. In addition, time to complete cornea re-epithelialisation was proportionately correlated with the infiltrate size and increased age whereas larger epithelial defect significantly increased the risk of corneal perforation. Another study by the same group similarly observed the risk of corneal perforation in FK was significantly influenced by the increased size of infiltrate as well as the presence of hypopyon and involvement of 1/3 posterior cornea at presentation. This was similarly observed in our study where increased age and large infiltrate size (>3 mm) served as significant negative predictive factors for visual outcome and corneal healing.
Compared to our recent bacterial keratitis study, FK was shown to be associated with poorer visual outcome, higher need for hospitalisation (with longer duration), longer healing time, and higher rate of complications. This was similarly observed in many other studies where FK was shown to fare worse than bacterial keratitis, highlighting the significant impact of FK on the patients, healthcare systems and economy (due to loss of work productivity).

Our study represents one of the largest studies in the UK specifically examining the epidemiology, risk factors, causes, and outcomes of FK. In addition, we examined the prognostic factors of various clinically important outcomes of FK, including the visual outcome and time to complete corneal healing. The main limitation of this study was the inclusion of culture-negative presumed FK cases. However, we had examined the medical case notes to ensure that all the included cases were true FK cases based on the clinical presentation and clinical course. This was further supported by the similar baseline characteristics of culture-positive and culture-negative FK cases in our study. The issue with low culture yield in infectious keratitis has been a recurrent clinical theme. In the future, it is envisaged that novel technologies, including polymerase chain reaction (PCR), IVCM, next generation sequencing, and artificial intelligence-assisted platforms would be able to enhance the diagnostic yield of infectious keratitis.

In conclusion, FK represents an uncommon but challenging ocular pathology that often results in poor visual outcome, with a high need for surgical interventions. Current therapeutic options are limited in clinical practice. Novel therapies such as host defense peptides (also known as antimicrobial peptides) and phage therapy have demonstrated promise as potential treatment for treating infectious keratitis and future investigations of these therapy for FK would be valuable.
REFERENCES

1. Ting DSJ, Ho CS, Deshmukh R, Said DG, Dua HS. Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance. Eye (Lond). 2021;35(4):1084-101.

2. Green M, Carnt N, Apel A, Stapleton F. Queensland Microbial Keratitis Database: 2005-2015. Br J Ophthalmol. 2019;103(10):1481-6.

3. Ting DSJ, Ho CS, Cairns J, Elsahn A, Al-Aqaba M, Boswell T, et al. 12-year analysis of incidence, microbiological profiles and in vitro antimicrobial susceptibility of infectious keratitis: the Nottingham Infectious Keratitis Study. Br J Ophthalmol. 2021;105(3):328-33.

4. Khor WB, Prajna VN, Garg P, Mehta JS, Xie L, Liu Z, et al. The Asia Cornea Society Infectious Keratitis Study: A Prospective Multicenter Study of Infectious Keratitis in Asia. Am J Ophthalmol. 2018;195:161-70.

5. Ting DSJ, Ho CS, Cairns J, Gopal BP, Elsahn A, Al-Aqaba M, et al. Seasonal patterns of incidence, demographic factors and microbiological profiles of infectious keratitis: the Nottingham Infectious Keratitis Study. Eye (Lond). 2021;35(9):2543-9.

6. Lin L, Duan F, Yang Y, Lou B, Liang L, Lin X. Nine-year analysis of isolated pathogens and antibiotic susceptibilities of microbial keratitis from a large referral eye center in southern China. Infect Drug Resist. 2019;12:1295-302.

7. Arshad S, Petsoglou C, Lee T, Al-Tamimi A, Carnt NA. 20 years since the Herpetic Eye Disease Study: Lessons, developments and applications to clinical practice. Clin Exp Optom. 2021;104(3):396-405.

8. Ting DSJ, Ghosh N, Ghosh S. Herpes zoster ophthalmicus. BMJ. 2019;364:k5234.

9. Carnt N, Robaei D, Minassian DC, Dart JKG. Acanthamoeba keratitis in 194 patients: risk factors for bad outcomes and severe inflammatory complications. Br J Ophthalmol. 2018;102(10):1431-5.

10. Brown L, Leck AK, Gichangi M, Burton MJ, Denning DW. The global incidence and diagnosis of fungal keratitis. Lancet Infect Dis. 2021;21(3):e49-e57.
11. Lin CC, Lalitha P, Srinivasan M, Prajna NV, McLeod SD, Acharya NR, et al. Seasonal trends of microbial keratitis in South India. Cornea. 2012;31(10):1123-7.

12. Cunha AM, Loja JT, Torrão L, Moreira R, Pinheiro D, Falcão-Reis F, et al. A 10-Year Retrospective Clinical Analysis of Fungal Keratitis in a Portuguese Tertiary Centre. Clin Ophthalmol. 2020;14:3833-9.

13. Ting DSJ, Bignardi G, Koerner R, Irion LD, Johnson E, Morgan SJ, et al. Polymicrobial Keratitis With Cryptococcus curvatus, Candida parapsilosis, and Stenotrophomonas maltophilia After Penetrating Keratoplasty: A Rare Case Report With Literature Review. Eye Contact Lens. 2019;45(2):e5-e10.

14. Ting DSJ, McKenna M, Sadiq SN, Martin J, Mudhar HS, Meeney A, et al. Arthrographis kalrae Keratitis Complicated by Endophthalmitis: A Case Report With Literature Review. Eye Contact Lens. 2020;46(6):e59-e65.

15. Prajna NV, Krishnan T, Rajaraman R, Patel S, Shah R, Srinivasan M, et al. Predictors of Corneal Perforation or Need for Therapeutic Keratoplasty in Severe Fungal Keratitis: A Secondary Analysis of the Mycotic Ulcer Treatment Trial II. JAMA Ophthalmol. 2017;135(9):987-91.

16. Said DG, Rallis KI, Al-Aqaba MA, Ting DSJ, Dua HS. Surgical management of infectious keratitis. Ocul Surf. 2021.

17. Lalitha P, Prajna NV, Manoharan G, Srinivasan M, Mascarenhas J, Das M, et al. Trends in bacterial and fungal keratitis in South India, 2002-2012. Br J Ophthalmol. 2015;99(2):192-4.

18. Lalitha P, Prajna NV, Oldenburg CE, Srinivasan M, Krishnan T, Mascarenhas J, et al. Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial. Cornea. 2012;31(6):662-7.

19. Dan J, Zhou Q, Zhai H, Cheng J, Wan L, Ge C, et al. Clinical analysis of fungal keratitis in patients with and without diabetes. PLoS One. 2018;13(5):e0196741.
20. Fernandes M, Vira D, Dey M, Tanzin T, Kumar N, Sharma S. Comparison Between Polymicrobial and Fungal Keratitis: Clinical Features, Risk Factors, and Outcome. Am J Ophthalmol. 2015;160(5):873-81.e2.

21. Ganguly S, Salma KC, Kansakar I, Sharma M, Bastola P, Pradhan R. Pattern of fungal isolates in cases of corneal ulcer in the western periphery of Nepal. Nepal J Ophthalmol. 2011;3(2):118-22.

22. Khurana A, Chanda S, Bhagat P, Aggarwal S, Sharma M, Chauhan L. Clinical characteristics, predisposing factors, and treatment outcome of Curvularia keratitis. Indian J Ophthalmol. 2020;68(10):2088-93.

23. Mascarenhas J, Lalitha P, Prajna NV, Srinivasan M, Das M, D'Silva SS, et al. Acanthamoeba, fungal, and bacterial keratitis: a comparison of risk factors and clinical features. Am J Ophthalmol. 2014;157(1):56-62.

24. Ong HS, Fung SSM, Macleod D, Dart JKG, Tuft SJ, Burton MJ. Altered Patterns of Fungal Keratitis at a London Ophthalmic Referral Hospital: An Eight-Year Retrospective Observational Study. Am J Ophthalmol. 2016;168:227-36.

25. Ting DSJ, Cairns J, Gopal BP, Ho CS, Krstic L, Elsahn A, et al. Risk Factors, Clinical Outcomes and Prognostic Factors of Bacterial Keratitis: The Nottingham Infectious Keratitis Study. Front Med (Lausanne). 2021;8:715118.

26. Lange C, Feltgen N, Junker B, Schulze-Bonsel K, Bach M. Resolving the clinical acuity categories "hand motion" and "counting fingers" using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol. 2009;247(1):137-42.

27. Tan SZ, Walkden A, Au L, Fullwood C, Hamilton A, Qamruddin A, et al. Twelve-year analysis of microbial keratitis trends at a UK tertiary hospital. Eye (Lond). 2017;31(8):1229-36.

28. Ting DSJ, Settle C, Morgan SJ, Baylis O, Ghosh S. A 10-year analysis of microbiological profiles of microbial keratitis: the North East England Study. Eye (Lond). 2018;32(8):1416-7.
29. Tavassoli S, Nayar G, Darcy K, Grzeda M, Luck J, Williams OM, et al. An 11-year analysis of microbial keratitis in the South West of England using brain-heart infusion broth. Eye (Lond). 2019;33(10):1619-25.

30. Keay LJ, Gower EW, Iovieno A, Oechsler RA, Alfonso EC, Matoba A, et al. Clinical and microbiological characteristics of fungal keratitis in the United States, 2001-2007: a multicenter study. Ophthalmology. 2011;118(5):920-6.

31. Galarreta DJ, Tuft SJ, Ramsay A, Dart JK. Fungal keratitis in London: microbiological and clinical evaluation. Cornea. 2007;26(9):1082-6.

32. Khoo P, Cabrera-Aguas MP, Nguyen V, Lahra MM, Watson SL. Microbial keratitis in Sydney, Australia: risk factors, patient outcomes, and seasonal variation. Graefes Arch Clin Exp Ophthalmol. 2020;258(8):1745-55.

33. Wang L, Wang L, Han L, Yin W. Study of Pathogens of Fungal Keratitis and the Sensitivity of Pathogenic Fungi to Therapeutic Agents with the Disk Diffusion Method. Curr Eye Res. 2015;40(11):1095-101.

34. Manikandan P, Abdel-Hadi A, Randhir Babu Singh Y, Revathi R, Anita R, Banawas S, et al. Fungal Keratitis: Epidemiology, Rapid Detection, and Antifungal Susceptibilities of Fusarium and Aspergillus Isolates from Corneal Scrapings. Biomed Res Int. 2019;2019:6395840.

35. Song A, Deshmukh R, Lin H, Ang M, Mehta JS, Chodosh J, et al. Post-keratoplasty Infectious Keratitis: Epidemiology, Risk Factors, Management, and Outcomes. Front Med (Lausanne). 2021;8:707242.

36. Ting DSJ, Said DG, Dua HS. Interface Haze After Descemet Stripping Automated Endothelial Keratoplasty. JAMA Ophthalmol. 2019;137(10):1201-2.

37. Sharma N, Kaur M, Titiyal JS, Aldave A. Infectious keratitis after lamellar keratoplasty. Surv Ophthalmol. 2021;66(4):623-43.

38. Ting DSJ, Henein C, Said DG, Dua HS. Photoactivated chromophore for infectious keratitis - Corneal cross-linking (PACK-CXL): A systematic review and meta-analysis. Ocul Surf. 2019;17(4):624-34.
39. Prajna NV, Radhakrishnan N, Lalitha P, Austin A, Ray KJ, Keenan JD, et al. Cross-Linking-Assisted Infection Reduction: A Randomized Clinical Trial Evaluating the Effect of Adjuvant Cross-Linking on Outcomes in Fungal Keratitis. Ophthalmology. 2020;127(2):159-66.

40. Ting DSJ, Henein C, Said DG, Dua HS. Re: Prajna et al.: Cross-Linking-Assisted Infection Reduction (CLAIR): A randomized clinical trial evaluating the effect of adjuvant cross-linking on outcomes in fungal keratitis (Ophthalmology. 2020;127:159-166). Ophthalmology. 2020;127(8):e55-e6.

41. Khoo P, Cabrera-Aguas M, Watson SL. Microbial Keratitis After Corneal Collagen Cross-Linking for Corneal Ectasia. Asia Pac J Ophthalmol (Phila). 2021;10(4):355-9.

42. Ting DSJ, Bandyopadhyay J, Patel T. Microbial keratitis complicated by acute hydrops following corneal collagen cross-linking for keratoconus. Clin Exp Optom. 2019;102(4):434-6.

43. Prajna NV, Krishnan T, Mascarenhas J, Srinivasan M, Oldenburg CE, Toutain-Kidd CM, et al. Predictors of outcome in fungal keratitis. Eye (Lond). 2012;26(9):1226-31.

44. Prajna NV, Srinivasan M, Lalitha P, Krishnan T, Rajaraman R, Ravindran M, et al. Differences in clinical outcomes in keratitis due to fungus and bacteria. JAMA Ophthalmol. 2013;131(8):1088-9.

45. Rathi VM, Murthy SI, Mitra S, Yamjala B, Mohamed A, Sharma S. Masked comparison of trypan blue stain and potassium hydroxide with calcofluor white stain in the microscopic examination of corneal scrapings for the diagnosis of microbial keratitis. Indian J Ophthalmol. 2021;69(9):2457-60.

46. Somerville TF, Corless CE, Sueke H, Neal T, Kaye SB. 16S Ribosomal RNA PCR Versus Conventional Diagnostic Culture in the Investigation of Suspected Bacterial Keratitis. Transl Vis Sci Technol. 2020;9(13):2.

47. Holmgaard DB, Barnadas C, Mirbarati SH, O'Brien Andersen L, Nielsen HV, Stensvold CR. Detection and Identification of Acanthamoeba and Other Nonviral Causes of
Infectious Keratitis in Corneal Scrapings by Real-Time PCR and Next-Generation Sequencing-Based 16S-18S Gene Analysis. J Clin Microbiol. 2021;59(2).

48. Chidambaram JD, Prajna NV, Palepu S, Lanjewar S, Shah M, Elakkiya S, et al. In Vivo Confocal Microscopy Cellular Features of Host and Organism in Bacterial, Fungal, and Acanthamoeba Keratitis. Am J Ophthalmol. 2018;190:24-33.

49. Ung L, Bispo PJM, Doan T, Van Gelder RN, Gilmore MS, Lietman T, et al. Clinical metagenomics for infectious corneal ulcers: Rags to riches? Ocul Surf. 2020;18(1):1-12.

50. Lalitha P, Prajna NV, Sikha M, Gunasekaran R, Hinterwirth A, Worden L, et al. Evaluation of Metagenomic Deep Sequencing as a Diagnostic Test for Infectious Keratitis. Ophthalmology. 2021;128(3):473-5.

51. Ting DSJ, Foo VH, Yang LWY, Sia JT, Ang M, Lin H, et al. Artificial intelligence for anterior segment diseases: Emerging applications in ophthalmology. Br J Ophthalmol. 2021;105(2):158-68.

52. Tiwari M, Piech C, Baitemirova M, Prajna NV, Srinivasan M, Lalitha P, et al. Differentiation of Active Corneal Infections from Healed Scars Using Deep Learning. Ophthalmology. 2021.

53. Hung N, Shih AK, Lin C, Kuo MT, Hwang YS, Wu WC, et al. Using Slit-Lamp Images for Deep Learning-Based Identification of Bacterial and Fungal Keratitis: Model Development and Validation with Different Convolutional Neural Networks. Diagnostics (Basel). 2021;11(7).

54. Rampat R, Deshmukh R, Chen X, Ting DSW, Said DG, Dua HS, et al. Artificial Intelligence in Cornea, Refractive Surgery, and Cataract: Basic Principles, Clinical Applications, and Future Directions. Asia Pac J Ophthalmol (Phila). 2021;10(3):268-81.

55. Ting DSJ, Beuerman RW, Dua HS, Lakshminarayanan R, Mohammed I. Strategies in Translating the Therapeutic Potentials of Host Defense Peptides. Front Immunol. 2020;11:983.
56. Mayandi V, Xi Q, Leng Goh ET, Koh SK, Jie Toh TY, Barathi VA, et al. Rational Substitution of ε-Lysine for α-Lysine Enhances the Cell and Membrane Selectivity of Pore-Forming Melittin. J Med Chem. 2020;63(7):3522-37.

57. Mohammed I, Mohanty D, Said DG, Barik MR, Reddy MM, Alsaadi A, et al. Antimicrobial peptides in human corneal tissue of patients with fungal keratitis. Br J Ophthalmol. 2021;105(8):1172-7.

58. Ting DSJ, Goh ETL, Mayandi V, Busoy JMF, Aung TT, Periayah MH, et al. Hybrid derivative of cathelicidin and human beta defensin-2 against Gram-positive bacteria: A novel approach for the treatment of bacterial keratitis. Sci Rep. 2021;11(1):18304.

59. Górski A, Bollyky PL, Przybylski M, Borysowski J, Międzybrodzki R, Jończyk-Matysiak E, et al. Perspectives of Phage Therapy in Non-bacterial Infections. Front Microbiol. 2018;9:3306.